FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of FLT-201’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FLT-201 is expected to reach an annual total of $59 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FLT-201 Overview
FLT-201 is under development for the treatment of type 1 Gaucher disease. The drug candidate is administered through intravenous route. It comprises of adeno-associated virus (AAV) vector encoding GBA1 gene. The drug candidate is developed based on next-generation proprietary AAV vector platform.
Spur Therapeutics Overview
Freeline Therapeutics Holdings Plc (Freeline), a subsidiary of Syncona Ltd, is a biotechnology company that develops transformative gene therapies for the treatment of debilitating diseases. The company utilizes the AAV vector and AAVS3 platform to deliver functional copies of therapeutic genes into human liver cells. Its platform consists of in-house capabilities in research and clinical development. Freeline’s product pipeline includes FLT190, a liver-directed gene therapy to treat fabry disease and FLT201 for the treatment of gaucher disease. The company works with clinicians, researchers, and companies worldwide. It serves the pharmaceutical and healthcare sectors. The company operates in Germany and the US. Freeline is headquartered in Stevenage, England, the UK.
For a complete picture of FLT-201’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
